Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 17325277.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.
Medical subject headings
- Brain Neoplasms
- Dacarbazine
- Glioma
- Risk Assessment